Our data align with these studies, suggesting that ASNS targeting—alone or in combination with agents disrupting amino acid transporters, redox homeostasis (e.g., glutathione synthase), or autophagy—could form the basis of next-generation SCLC treatment. The gene discussed is SLC38A7; the disease is small cell lung carcinoma.